- Pancreatic cancer is lethal not only because it grows, but because it spreads early and aggressively.
- New research suggests the tumour can reprogramme surrounding tissue to create physical and biological pathways that help it invade nerves and travel beyond the pancreas.
- By identifying a protein called periostin and specific supportive cells in the tumour environment, the work points towards targets that could potentially slow invasion before metastasis takes hold.
Most pancreatic cancers are adenocarcinomas, arising from glandular cells involved in digestive secretions.
Although pancreatic cancer is less common than some other cancers, its outcomes are disproportionately poor.
Many people are diagnosed late and even when surgery is possible, recurrence and spread are frequent. This gap between incidence and mortality has driven intense interest in what makes pancreatic tumours so difficult to control.
One hallmark of aggressive pancreatic cancer is perineural invasion, where cancer cells infiltrate and spread along nerves.
This matters for two reasons.
First, nerve invasion is associated with severe pain and worsening quality of life. Second, nerves act like routes through tissue, offering cancer cells a structure they can follow to move beyond the primary tumour.
Perineural invasion is therefore often treated as a marker of aggressiveness and a sign that the disease is already behaving in a way that increases metastatic risk.
The new study focused on the tumour microenvironment, particularly the stroma, the dense connective tissue that surrounds and supports the tumour.
For years, the stroma was sometimes treated as a bystander, a structural consequence of tumour growth. Increasingly, it is seen as an active participant.
In pancreatic cancer, the stroma can become thick, fibrous and inflamed, creating a hostile architecture that paradoxically protects the tumour from treatment.
Using advanced methods that combine gene activity profiling with spatial mapping inside tumour samples, the researchers analysed pancreatic cancer tissue and identified a particular pattern: stellate cells producing high levels of periostin were associated with perineural invasion.
Stellate cells are support cells in the pancreas that can be activated during injury or disease.
In cancer, they can become co-opted, producing proteins that remodel the extracellular matrix, the scaffolding that holds tissue together.
Periostin is one such protein. It plays a role in reshaping the extracellular matrix, changing how dense, aligned or penetrable the tissue becomes.
For a tumour to invade, it must push through this matrix. By altering the matrix, periostin can effectively “pave” routes through surrounding tissue, making it easier for tumour cells to reach nerves.
Once the cancer reaches a nerve, the nerve becomes a conduit, helping tumour cells extend their reach.
This matrix remodelling links directly to another notorious feature of pancreatic cancer: desmoplasia. Desmoplasia is the build-up of dense fibrous tissue around the tumour, made up of activated support cells, collagen and other matrix components.
While it might sound like the body is trying to wall off the tumour, the end result often favours the cancer.
The thickened tissue can compress blood vessels, reduce oxygen delivery and make it physically harder for chemotherapy drugs and immune cells to penetrate.
That barrier effect is one reason pancreatic cancer has been stubbornly resistant to many treatments that work better in other cancers.
Clinically, perineural invasion is common and often discovered only after surgery when tissue is examined.
That timing is part of the tragedy. By the time invasion is documented, it may already have contributed to spread. This is why targets that intervene earlier are so attractive.
If periostin-positive stellate cells help tumours gain access to nerves, then blocking periostin signalling or altering stellate cell activity could, in theory, reduce invasion and slow progression.
There is precedent for targeting periostin in other cancers, including efforts using antibodies designed to block it.
Whether that approach will translate to pancreatic cancer remains uncertain, but identifying a specific molecule and cell population linked to nerve invasion gives researchers something concrete to test.
You may be interested in:
- Pancreatic cancer triggered by some oral microbes
- Scientists discover pancreas can make its own GLP-1
- New test can accurately detect early-stage pancreatic cancer
It also fits the broader shift towards precision oncology, where treatment is guided not only by tumour type but by molecular features of the tumour and its environment.
The work does not solve pancreatic cancer, and it does not mean a periostin-blocking drug will suddenly change outcomes.
Tumour biology is redundant, meaning cancers often find alternative routes when one pathway is blocked.
Still, mapping how pancreatic tumours manipulate their surroundings is essential progress. It reframes pancreatic cancer spread as an engineered process involving the tumour and its supportive ecosystem, not just an inevitable consequence of fast growth.
That shift opens the door to strategies aimed at disabling invasion itself, which is arguably where pancreatic cancer does its most devastating work.
